Bai R, Taylor G F, Schmidt J M, Williams M D, Kepler J A, Pettit G R, Hamel E
Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Mol Pharmacol. 1995 May;47(5):965-76.
We have prepared [3H]dolastatin 10 and examined its interactions with tubulin. Binding kinetics appeared to be biphasic, with a rapid initial reaction that could not be accurately measured, followed by a slower second reaction. Bound drug was stable in centrifugal gel filtration, column gel filtration, and high performance liquid chromatography gel filtration, but the bound drug could be displaced by an active isomer of dolastatin 10. Scatchard analysis of binding data was consistent with two classes of binding sites. However, dolastatin 10 induced an aggregation reaction upon binding to tubulin, complicating analysis of the data, and incorporation of [3H]dolastatin 10 into large aggregates was readily demonstrated. The chromatographic properties of the smallest radiolabeled species that could be documented were most consistent with a complex consisting of two molecules of alpha/beta-tubulin dimer and two molecules of [3H]dolastatin 10. The coexistence of an aggregation reaction with a binding reaction at a single site probably underlies the biphasic binding kinetics and the biphasic Scatchard plot. Of peptides that strongly inhibit tubulin polymerization (dolastatin 10, dolastatin 10 isomers, segments, and analogs, dolastatin 15, and phomopsin A), only those previously shown to be strong inhibitors of vinblastine binding and nucleotide exchange also strongly inhibited [3H]dolastatin 10 binding and induced tubulin aggregation (dolastatin 10 itself, two chiral isomers of dolastatin 10, and phomopsin A). The morphology of dolastatin 10-induced aggregates was compared with that of vinblastine-induced aggregates under a variety of reaction conditions. With both drugs the aggregates had a more organized appearance when microtubule-associated proteins were included in the reaction.
我们制备了[3H]多拉司他汀10,并研究了其与微管蛋白的相互作用。结合动力学似乎呈双相性,先是一个无法精确测量的快速初始反应,随后是较慢的第二个反应。结合的药物在离心凝胶过滤、柱凝胶过滤和高效液相色谱凝胶过滤中稳定,但结合的药物可被多拉司他汀10的活性异构体取代。结合数据的Scatchard分析与两类结合位点一致。然而,多拉司他汀10与微管蛋白结合时会诱导聚集反应,使数据分析复杂化,并且很容易证明[3H]多拉司他汀10掺入大聚集体中。能够记录的最小放射性标记物种的色谱特性与由两个α/β-微管蛋白二聚体分子和两个[3H]多拉司他汀10分子组成的复合物最为一致。在单个位点上聚集反应与结合反应共存可能是双相结合动力学和双相Scatchard图的基础。在强烈抑制微管蛋白聚合的肽(多拉司他汀10、多拉司他汀10异构体、片段和类似物、多拉司他汀15和腐草霉素A)中,只有那些先前被证明是长春碱结合和核苷酸交换的强抑制剂的肽也强烈抑制[3H]多拉司他汀10结合并诱导微管蛋白聚集(多拉司他汀10本身、多拉司他汀10的两种手性异构体和腐草霉素A)。在各种反应条件下,比较了多拉司他汀10诱导的聚集体与长春碱诱导的聚集体的形态。在反应中加入微管相关蛋白时,两种药物诱导的聚集体外观都更有组织性。